Consensus Valerio Therapeutics BOERSE MUENCHEN

Equities

C4X

FR0010095596

Market Closed - BOERSE MUENCHEN Other stock markets 03:43:56 2024-06-11 pm EDT			5-day change	1st Jan Change
0.1196 ^EUR	+0.34%		+17.09%	-21.32%

May. 22	Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	CI
Apr. 30	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Valerio Therapeutics

Price target over the last 5 years

History of analyst recommendation changes

0ce451cb6c09e26aa.MJ4jwO3pM2Ct1T4_Cfdka9fv9IECAN4f8va21ktmnfc.dMgXjZWQUCLyt3Vba8A7KJrcxvlvafN3h5LkhwhTsJFf6m2ko45wGc6sXQ~688a468533108b4d4f85379314774c26

Analyst Recommendations on Valerio Therapeutics

Onxeo : Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation	20-05-29	PU
Bryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” Recommendation	20-05-27	GL
Onxeo : Bryan Garnier & Co Initiates the Coverage of Onxeo with a “Buy” Recommendation	20-05-27	BU

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1076 EUR

Average target price

1.2 EUR

Spread / Average Target

+1,015.24%

High Price Target

1.2 EUR

Spread / Highest target

+1,015.24%

Low Price Target

1.2 EUR

Spread / Lowest Target

+1,015.24%

Consensus detail

Consensus revision (last 18 months)

Annual profits - Rate of surprise

Company calendar